Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 557-562

  De Vos, M ^a   Dewit, O ^b   D'Haens, G ^c   Baert, F ^d   Fontaine, F ^e   Vermeire, S ^f   Franchimont, D ^g   Moreels, T ^h   Staessen, D ⁱ   Terriere, L ^j   Vander Cruyssen, B ^a   Louis, E ^k  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Heilig Hart Ziekenhuis   (Belgium)

^e Clinique Saint Joseph   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ AZ Monica   (Belgium)

^j ZNA Middelheim   (Belgium)

^k UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

Calprotectin; Infliximab; Ulcerative Colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; METHOTREXATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; ENDOSCOPY; FECES ANALYSIS; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SCORING SYSTEM; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SIGMOIDOSCOPY; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84860833622     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.11.002     Document Type: Article

References (13)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med Dec 8, 2005, 353(23):2462-2476. Erratum in: N Engl J Med. 2006 May 18;354(20):2200.
2. Barreiro-de Acosta M., Lorenzo A., Mera J., Dominguez-Muñoz J.E. Mucosal healing and steroid sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis Dec 2009, 3(4):271-276.
3. Røseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997, 58(2):176-180.
4. Costa F., Mumolo M.G., Ceccarelli L., Bellini M., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut Mar 2005, 54(3):364-368.
5. Schoepfer A.M., Trummler M., Seeholzer P., Criblez D.H., Seibold F. Accuracy of four faecal assays in the diagnosis of colitis. Dis Colon Rectum Oct 2007, 50(10):1697-1706.
6. Gisbert J.P., Bermejo F., Pérez-Calle J.L., Taxonera C., Vera I., McNicholl A.G., et al. Faecal calprotectin and lactoferrin for the prediction of inflammatory bowel relapse. Inflamm Bowel Dis Aug 2009, 15(8):1190-1198.
7. D'Incà R., Dal Pont E., Di Leo V., Benazzato L., Martinato M., Lamboglia F., et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol Aug 2008, 103(8):2007-2014.
8. Ho G.T., Lee H.M., Brydon G., Ting T., Hare N., Drummond H., et al. Faecal calprotectin predicts the clinical course of acute severe colitis. Am J Gastroenterol Mar 2009, 104(3):673-678.
9. Turner D., Leach S.T., Mack D., Uusoue K., McLernon R., Hyams J., et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicenter comparison of predicting outcomes and monitoring response. Gut Sep 2010, 59(9):1207-1212.
10. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med Oct 9, 1997, 337(15):1029-1035.
11. Jürgens M., Laubender R.P., Hartl F., Weidinger M., Seiderer J., Wagner J., et al. Disease activity, ANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol Aug 2010, 105(8):1811-1819.
12. Ferrante M., Vermeire S., Katsanos K.H., Noman M., Van Assche G., Schnitzler F., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis Feb 2007, 13(2):123-128.
13. Sylvester F.A., Turner D., Draghi A., Uuosoe K., McLernon R., Koproske K., et al. Faecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel 2011, 17(8):1726-1730.